Cellectis (CLLS) Q4 2025 earnings review
AZ Partnership Fuels Revenue Surge, But Financial Losses Deepen
Cellectis delivered a 76% YoY surge in full-year revenue to $72.9M in FY25, overwhelmingly driven by its AstraZeneca collaboration. However, this top-line success masks a rapidly deteriorating bottom line. Q4 net income experienced a reversing trend, plunging from a $5.9M profit in 24Q4 to a $26.3M loss in 25Q4. The full-year net loss widened to $67.6M, heavily impacted by a massive $34.9M net financial loss stemming from adverse FX movements (USD devaluation) and EIB warrant valuations. While clinical data for its lead UCART programs remains highly promising, the extreme volatility in financial expenses and total reliance on a single partner for revenue warrant caution. The company's $211M cash position secures runway into H2 2027, bridging the gap to crucial Q4 2026 clinical milestones.
🐂 Bull Case
The AZ JRCA is executing well, generating $71.9M of the company's $72.9M FY25 revenue. This provides non-dilutive capital and deep-pocketed validation of the TALEN platform.
Lasme-cel (UCART22) demonstrated a 100% ORR in its target Phase 2 population, with all patients becoming transplant eligible. A BLA submission is firmly targeted for 2028.
🐻 Bear Case
99% of FY25 revenue came from a single customer (AstraZeneca). Any strategic pivot or delay by AZ poses an existential threat to Cellectis's top line.
A $22.2M foreign exchange loss and $14.7M loss on EIB warrants wiped out operating progress, proving that Cellectis's bottom line is highly vulnerable to macroeconomic crosswinds.
⚖️ Verdict: ⚪
Neutral. The underlying science and clinical execution are stable and accelerating. However, the financial structure is precarious, with earnings obliterated by non-operational FX and derivative losses, and top-line health resting entirely on the AstraZeneca partnership.
Key Themes
AstraZeneca Partnership Dominates the Top Line
The AstraZeneca Joint Research and Collaboration Agreement (JRCA) is the absolute engine of Cellectis's revenue. In FY25, collaboration agreements generated $72.1M, with AZ accounting for 99% of total company revenue. This is an accelerating trend compared to FY24, driven by the fulfillment of performance obligations across the initial research plans. The recent amendment to the JRCA restructures milestone payments (now up to $253M per candidate product), expanding the long-term revenue ceiling.
Lasme-cel (UCART22) Path to BLA Crystallizing
Clinical data for the lead asset, lasme-cel, is showing highly compelling efficacy. In the target Phase 2 population of the BALLI-01 study, Cellectis reported a 100% ORR (n=9), with all patients becoming eligible for transplant. Median overall survival in MRD-negative patients hit 14.8 months. With the Phase 2 pivotal trial now enrolling, management has laid down a clear marker: BLA submission in 2028.
Financial Expenses Decimate the Bottom Line
A reversing trend in net financial items crippled the 2025 bottom line. Cellectis posted a net financial loss of $34.9M, compared to a gain of $22.8M in 2024. This was driven by a $22.2M foreign exchange loss due to the USD's devaluation against the Euro (impacting USD cash holdings), and a $14.7M loss on the fair value measurement of EIB warrants. This non-operational drag doubled the company's net loss despite a $31M increase in revenue.
Servier Arbitration Fracture
The legacy partnership with Servier continues to deteriorate. Following an arbitration initiated by Cellectis, the tribunal ordered the partial termination of the Servier License Agreement specifically regarding UCART19 V1. While Cellectis must engage in good-faith negotiations to grant a direct license to Allogene upon request, this disrupts the commercialization pathway for the CD19 program and highlights partnership instability outside of AZ.
In-House Manufacturing Strategy Paying Off
The strategic shift to internal manufacturing in Raleigh, NC, and Paris, France, is supporting clinical momentum. Lasme-cel product used in the BALLI-01 study is now fully manufactured in-house. In vitro comparability studies suggest this new process ('UCART22 P2') is more potent than the externally produced version, correlating with a higher preliminary response rate (67% at dose level 2 vs 50% previously) and better expansion profiles.
Next-Gen Gene Editing Tech Showcased
Cellectis continues to push beyond baseline TALEN technology. The company published data on circular single-stranded DNA (cssDNA) achieving over 40% knock-in efficiency without viral vectors like AAV6. Additionally, TALE base editors (TALEB) demonstrated precise DNA editing without double-strand breaks or off-target bias at CTCF binding sites. These innovations fortify the IP moat against CRISPR-based competitors.
Other KPIs
Reversing trend. Cash flow from operations flipped from a positive $23.0M in FY24 back to a burn of $39.4M in FY25. This was driven by $50.5M in supplier payments and $40.0M in wages, partially offset by $36.9M in cash-in from the AZ collaboration. Careful working capital management is required as clinical trials scale.
Stable/Slightly Accelerating. Up 3.3% YoY from $90.5M in 2024. The increase was driven by a $4.2M rise in personnel expenses aligned with the clinical roadmap and manufacturing scale-up, offset slightly by a decrease in external purchases.
Consists of $61.5M in cash and cash equivalents and $144.8M in fixed-term deposits. This provides a stated runway into the second half of 2027, covering the critical data readouts scheduled for late 2026.
Guidance
Management expects the first interim analysis for the pivotal Phase 2 BALLI-01 trial of lasme-cel (n=40) in Q4 2026. This is the most critical near-term catalyst for the company.
The full Phase 1 dataset for eti-cel in r/r NHL (NATHALI-01 trial), including the low-dose IL-2 cohort, is expected in Q4 2026. This will define the go-forward strategy for the CD20/CD22 dual-targeting asset.
Long-term regulatory target established. Cellectis anticipates submitting a Biologics License Application for lasme-cel in 2028, marking its transition from a clinical-stage to a commercial-stage company.
Key Questions
FX Hedging Strategy
Given the massive $22.2M foreign exchange loss recorded in 2025 due to USD devaluation against the Euro, why has the company not implemented a more aggressive hedging strategy to protect its USD-denominated cash runway?
Servier/Allogene Arbitration Fallout
With the arbitral tribunal ordering partial termination of the Servier agreement for UCART19 V1, what are the exact financial and clinical implications for Cellectis, and how quickly can a direct license with Allogene be established to avoid development delays?
AstraZeneca Collaboration Depth
With AZ accounting for 99% of FY25 revenue, what visibility do you have into AZ exercising their exclusive options on the candidate products before IND filings, and what is the expected cadence of milestone payments over the next 24 months?